Get Our FREE Newsletter

Sign Up

BioNTech eyes up to 17 billion euros in vaccine revenue in 2022

Spread the love

In presentation slides for J.P. Morgan’s annual healthcare conference, which is being held virtually this year, BioNTech said it expects 13 billion to 17 billion euros in revenue accruing to it from the vaccine this year, which compares with a guidance of 16 billion-17 billion euros for 2021.

($1 = 0.8824 euros)

This post was originally published on this site